AstraZeneca Pharma India (506820) Q3 24/25 earnings summary

Executive summary

• Achieved a 44% year-over-year increase in revenue for Q3 2024, with total revenue from operations rising by Rs. 1,345 million compared to the same quarter last year.

• Strong growth across therapeutic areas, especially Oncology (up 67%) and Biopharmaceuticals (up 10%) year-over-year.

• Focused on innovation and expanding access to healthcare, with continued investment in specialist disease areas.

Financial highlights

• Q3 2024 revenue from operations: Rs. 4,402.9 million, up from Rs. 3,057.9 million in Q3 2023.

• Profit before exceptional items and tax for Q3 2024: Rs. 755.7 million, up from Rs. 204.0 million in Q3 2023.

• Profit after tax for Q3 2024: Rs. 308.5 million, compared to Rs. 158.0 million in Q3 2023.

• Earnings per share (basic and diluted) for Q3 2024: Rs. 12.34, up from Rs. 6.32 in Q3 2023.

• Total comprehensive income for Q3 2024: Rs. 291.3 million.

Outlook and guidance

• Strategy focused on growth through innovation and expanding the next generation of therapeutics.

• Continued emphasis on increasing access to healthcare and strengthening healthcare system resilience.